TABLE 4

The cost-effectiveness Outcomes for the Trial and the Hypothetical Scenarios

CPAP (n = 338)nHF (n = 338)Difference (95% CI)PCost-effectiveness
With back-up CPAP (trial)
Cost, A$20 606 20 753 −147 (−3025 to 2732) .92 — Effectiveness, intubation rate, % 5.9 7.7 −1.8 (−5.6 to 2.0) .36 No difference in cost or effectivenessa Effectiveness, NICU transfer rate, % 9.2 8.6 0.6 (−3.7 to 4.9) .79 No difference in cost or effectivenessb No back-up CPAP (hypothetical) Cost, A$ 20 606 21 615 −1009 (−3892 to 1874) .49 —
Effectiveness, intubation rate, % 5.9 13.9 −8.0 (−12.5 to −3.5) <.001 CPAP cheaper and more effective
Effectiveness, NICU transfer rate, % 9.2 15.7 −6.5 (−11.5 to −1.5) .01 CPAP cheaper and more effective
CPAP (n = 338)nHF (n = 338)Difference (95% CI)PCost-effectiveness
With back-up CPAP (trial)
Cost, A$20 606 20 753 −147 (−3025 to 2732) .92 — Effectiveness, intubation rate, % 5.9 7.7 −1.8 (−5.6 to 2.0) .36 No difference in cost or effectivenessa Effectiveness, NICU transfer rate, % 9.2 8.6 0.6 (−3.7 to 4.9) .79 No difference in cost or effectivenessb No back-up CPAP (hypothetical) Cost, A$ 20 606 21 615 −1009 (−3892 to 1874) .49 —
Effectiveness, intubation rate, % 5.9 13.9 −8.0 (−12.5 to −3.5) <.001 CPAP cheaper and more effective
Effectiveness, NICU transfer rate, % 9.2 15.7 −6.5 (−11.5 to −1.5) .01 CPAP cheaper and more effective

—, not applicable.

a

CPAP appeared cheaper and more effective; however, the cost and effectiveness differences are neither statistically significant nor economically or clinically meaningful.

b

Nasal HF appeared more costly and more effective; however, the cost and effectiveness differences are neither statistically significant nor economically meaningful.

Close Modal